Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Thoracic Neoplasms 1Small Cell Lung Carcinoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Carcinoma 1

Interventions

Carboplatin 15Pemetrexed 8Paclitaxel 6pembrolizumab 5osimertinib 4atezolizumab 4Gemcitabine 4Erlotinib Hydrochloride 4entinostat 3durvalumab 3Cisplatin 3selpercatinib 2pralsetinib 2camrelizumab 2apatinib 2Vinorelbine 2Radiosurgery 2Nivolumab 2Injections 2Gefitinib 2Bevacizumab 2130-nm albumin-bound paclitaxel 2toripalimab 1taletrectinib 1sotorasib 1sintilimab 1repotrectinib 1pegylated granulocyte colony-stimulating factor 1patritumab 1necitumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thoracic Neoplasms × efineptakin alfa × Thoracic × Clear all
NCT04332653 2026-03-09

NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

NeoImmuneTech

Phase 1/2 Completed
215 enrolled 30 charts
BreastGastrointestinalGynecologicThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Thoracic Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡